2Q26 Business and Financial Highlights

• Bora delivered historically record-high quarterly revenues of NT$5,889 million in 2Q26, up 47.2% quarter-over-quarter driven by broad-based operational momentum, with basic EPS of NT$4.36.
• CDMO revenue growth and increased site utilization rates, along with strong growth in the rare disease business and a return to growth for generics business of the Pharma Sales operations lifted group profitability, with gross margin expanding to 41.3% from 36.0% and operating margin reaching 16.8% from 10.2% in 1Q26. Excluding one-time costs related to the Weider Global Nutrition transaction, operating margin was approximately 18%.
• CDMO’s strong backlog of US$317 million as of end of 2Q26, another historical high following a strong quarter, signals that Bora’s core business continued to perform with higher demand.
• Pharma Sales’ rare disease franchise continues to show double digit sequential growth and the increased demand from government channels during the quarter with stabilized pricing in DLS has lifted the generics business back to normal.
• Reflecting Bora’s recent increase in investment in Sunway Biotech, from 35.97% to 42.27% and subsequent acquisitions of Weider Global Nutrition’s, the Company has introduced “Consumer Healthcare (CHC)” as a new segment in its revenue mix disclosure beginning this quarter. In 2Q26, revenues from CHC were NT$824.76 million in 2Q26, a 354.4% increase QoQ and 234.3% YoY, and contributed to 14% of the Bora Groups consolidated revenues, an all-time high.
• Cash-on-hand reached an all-time high of NT$8,431 million as the Company was preparing for MacroGenics Inc.’s Rockville facility acquisition.
• The Company has kicked off a group-wide AI in Manufacturing, BORA AIM, program aimed at improving process efficiency across sites, spanning engineering, quality and production. Bora has also signed a partnership with Insilico Medicine for AI drug discovery. The first 6 months will focus on beta version testing of the Bora AIM agents and AI champions to drive process consolidation.
• Share capital increased 0.3% during the quarter from employee stock option exercise.

Mr. Bobby Sheng, Chairman of Bora Group, stated, “We are pleased to announce Bora Group’s return to strong operating profits and double to triple-digit growth on all key margins sequentially, as well as demonstrate that our soft 1Q26 performance was anomalous rather than structural. Our impressive sequential improvement was driven entirely by strong demand from both our CDMO and Pharma Sales businesses, with 2Q26 manufactured batches reaching 0.38 billion doses, led by increased commercial production in Maple Grove and Zhunan sites and a full quarter of operations in the Maryland injectable facility, while our flagship products DLS and VIGAFYDE® in Pharma Sales continues to secure leading market share.

Our focus right now is execution. CAPEX investments in our mature sites, including facilities in Taiwan and in Canada, continue to deliver operational leverage driven by gross margin expansion, and our recently acquired oral solid dose facility in Maple Grove continues to show stellar and impactful demand as we sign more projects. Our 12-month rolling backlog is at historic high in almost all our sites, despite projected manufacturing delays at our Maryland injectable facility as we diligently respond to FDA audit observations from a recent audit. Bora Group’s commitment to the fast-growing Biologics manufacturing industry took another big step as we look to integrate 12,000 liters of capacity, and 3 commercial products from our Rockville facility, as well as see revenue recognition from this acquisition starting Q3. As Bora’s CDMO footprint expands in the US, we continue to capture durable, high-value demand as customers increasingly prioritize supply security and onshore capacity.

In addition, we are seeing sustained growth and improved gross margins in the Vigabatrin franchise, our most important, rare disease franchise, thanks to renegotiations with our partner vendors. Accelerated state and government orders for generics products increased 2Q26 revenues and 6 new generics launches have also supported a more diversified generics portfolio. Together, the advancement in rare disease franchise and generics business has positioned Bora’s Pharma Sales business, operating under the name Upsher-Smith, in a far stronger state than it was just a quarter ago.

As announced in July, we are excited to be developing a group-wide AI in Manufacturing program, BORA AIM, aimed at improving process efficiency across sites, spanning engineering, quality and production. We also announced a partnership with Insilico Medicine to enhance our understanding of AI drug discovery and create more customized AI manufacturing platforms for AIDD small molecules. In the next 12 months, Bora Group will be ready to showcase some exciting AI-enabled CDMO platforms that will truly add value to our partners and sharpen the overall competitive advantages of Bora Group.

As our momentum carries Bora into the second half of the year, we expect margins of our flagship products in Pharma Sales and CHC businesses to hold steady on continuous revenue growth, and improved efficiencies in the CDMO business in addition to consolidation of new revenues from the Rockville facility.”

2Q26 Operational Achievements & 2026 Outlook

Global CDMO Operations

Revenues increased 30.3% year-over-year and 29.0% quarter-over-quarter including internal orders, and 33.0% and 40.2% external orders only, or NT$2,116.4 million. The growth was primarily driven by a strong rebound in injectables following the semi-annual maintenance in 1Q26 and same period last year, and demand acceleration overall as we continue to meet the increasing backlog.

CDMO business also signed a record high US$378.2 million in total external wins. Highlighted by a 10+2-year, multi product commercial contract in our Maple Grove facility with a new top-20 pharma company, and 14 new molecules from pre-commercial programs from multiple new customers. Bora is confident in its mid- to long-term growth trajectory as pharma and biotech companies continue to look for US based CDMOs as a part of their efforts to onshore US production and improve supply chain resilience.

During the quarter, 0.38 billion doses, or 109 molecules, were developed and manufactured. Contribution from the top 20 global pharmaceutical companies stood at roughly 30% and should increase drastically in the next 8 quarters.

Looking at 3Q26, the Company is highly optimistic, with our backlog having climbed to an unprecedented level even after a strong quarter of manufacturing output. We do anticipate some timing shifts in revenue recognition related to scheduled semi-annual maintenance at our Maryland injectable site, alongside targeted quality-enhancement activities in connection with observations on passive RABS (Restricted Access Barrier System) line received from an FDA audit that took place 2Q26. However, there has been no reduction in total commercial batch productions in 2026 as we speak and several existing clients have initiated transfers to the FlexPro isolator filling lines. RFP activity has risen, with the first GMP PPQ campaign starting in August. On the newest, isolator-based AST lines, factory acceptance testing (FAT) is planned for Q326, with qualification to follow in 2027, expanding our ability to onboard small-scale isolator programs, including tech transfers.

On biologics, Rockville facility revenue recognition started in the first month of 3Q26 and the site has confirmed that it is on track to deliver batch production volumes ahead of last year’s run rate of around 13 batches for the remainder of 2026. We anticipate one-time transaction costs from this acquisition of approximately 3% of the purchase price including legal and FA fee and transition related expenses as stated in the Transition Service Agreement. The Rockville acquisition expands biologics capacity and brings integrated drug substance (DS) and drug product (DP) capabilities under one roof, strengthening our end-to-end service offering and attracting more inbound opportunities and higher value conversion with cross selling opportunities for our injectable business.

For our strategic investment in Tanvex Biopharma, the main Bora Biologics platform company, although the business still operates at a loss, Tanvex has built a strong presence in international conferences, especially Bio International in the US in June. We have seen a positive uptick in pipeline from leading biotechs and heavy weight biopharmas, and stable demand for early-stage PD programs in Zhubei. The Rockville acquisition is expected to orchestrate and accelerate opportunities for Tanvex in the coming quarters.

Pharma Sales Operations

Revenues decreased 2.7% year-over-year and increased 30.4% quarter-over-quarter, arriving at NT$2,934.04 million in 2Q26. The year-over-year decrease was mainly due to a product rationalization program in 2025 that lead to the withdrawal of a basket of legacy generics products.

During the quarter, specialty and brand came in strongly, up 58.8% for the quarter QoQ and displayed almost 50% growth against 2025 run rate. The rare-disease Vigabatrin franchise demand is robust, and our continuous investment in the segment has resulted in much broader patient access compared to when we acquired Upsher-Smith 28 months ago. On coverage, we are on track to achieve year-end formulary goal of >50%, supported by more regional plans and strong physician adoption as they gain experience with VIGAFYDE®. The Company has also renegotiated contracts with suppliers, leading to improved gross margins for the franchise during the quarter and expects full economic contribution starting 3Q26. Simultaneously, the Company out-licensed its non-core assets, Stiripentol generics and 505(b)(2), during the quarter, fully capturing the economic value of these drug assets to enable fueled and renewed focus on core specialty and brand business.

The generics business returned to stability as Upsher-Smith successfully defended flagship product DLS. High value generics advanced 20.6% sequentially from downstream restocking, narrowing the year-to-date YoY decline against 2025 run rate to high teens.

Having executed our way through specialty and brand business growth and generics portfolio optimization, we have returned to the 2023–2024 peaks of Pharma Sales performance but with healthier and more resilient operating profits. As of now, Upsher-Smith sees 6 ANDA pending approval.

CHC Operations

Bora Group has increased holdings of Sunway Biotech to 42.27% through a private placement at $NT 596 million. Subsequently, Sunway completed the acquisition of Weider Global Nutrition (WGN), a global nutritional supplements company with offices in the US, Spain, and Germany and products sold in over 60 countries. Benefitting from the consolidation of WGN that started in May, Consumer Health business totaled NT$824.76 million in 2Q26, a 354.4% increase QoQ and 234.3% YoY. Focusing on longevity and sports nutrition, WGN’s distribution strength is expected to meaningfully contribute to the CHC business in 2026 and beyond and shall deliver vertical-integration synergies to Sunway’s existing ingredients’ manufacturing operations. Together, the WGN acquisition is expected to catapult Sunway Biotech into a leading global nutritional supplements company and substantially accelerate top and bottom-line improvements in the future.

Recent Investor Conference

Bora will host English online earnings call at 8:00 a.m. Taiwan time on Aug. 14^th, 2026. The event will cover the Company’s 2Q26 financial and business results and 2H26 outlook.

English Online Earnings Presentation Link: https://teams.microsoft.com/meet/225504163505748?p=UyyncWl1CnOzjBCNKD

Bora will participate in Goldman Sachs 2026 CDMO day in Singapore in Sept. For 1:1 meetings with management, please contact your GS representative.

Bora 2026 Earnings Schedule

Q3 2026: Expected in the 2^nd week of Nov 2026
Q4 2026: Expected in the 2^nd week of Mar 2027

Hashtag: #BoraGroup

The issuer is solely responsible for the content of this announcement.

About Bora

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com

Disclaimer:

This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

The “Mini Moon Quartet” Unveils Four Distinct Flavors Crafted with Elegance

HONG KONG SAR – Media OutReach Newswire – 13 August 2026 – As the Mid-Autumn moon peaks, reunion means more than a gathering over a meal. It is a generational festival memory stirred by timeless flavors. This year, Yung Kee Restaurant continues its theme “Indulging in Moonlit Delights, Embracing the Joy of Reunion” to unveil its 2026 Mid-Autumn mooncake collection. Three enticing new flavors – Mini Matcha Lava Custard, Mini Taro Custard with Coconut Milk, and Mini Red Bean Paste with Mandarin Peel – join the festival-favorite Mini Lava Custard Mooncakes to form the all-new “Mini Moon Quartet”. Paired alongside time-honored classics – Lotus Seed Paste Mooncakes with Double Yolks and Mixed Nuts Mooncakes with Chinese Ham, these exquisite combinations bring heartfelt warmth and variety to every festive table.

“Mini Moon Quartet”: Savoring Distinctive and Exquisite Flavors

Crafting the perfect mooncake demands meticulous ingredient sourcing, precise heat control, and decades of artisanal skill. This year, Yung Kee presents the Mini Moon Quartet, each recipe thoughtfully tailored to showcase the natural character of its premium ingredients. From subtle tea aromas and creamy milk notes to the comfort of taro and mellow fragrance of aged mandarin peel, each mini mooncake offers a nuanced, multi-layered taste profile.

Mini Matcha Lava Custard Mooncake is made with top‑tier First‑Flush (Ichiban‑cha) tencha from Shiga Prefecture, stone‑milled at low temperature into a fine, vibrant powder. Blended with premium milk and rich cream, it reveals a silky molten center where velvety custard meets bold matcha. Each bite unfolds bold and velvety matcha followed by a gentle milk finish. Vibrant without bitterness, it leaves a soothing, lingering sweetness – striking an elegant balance between rich and refreshing.

Mini Taro Custard with Coconut Milk Mooncake is crafted with authentic Taiwanese taro, prized for its natural aroma and fluffy texture, then slow‑cooked to melt‑in‑your‑mouth perfection. Velvety taro paste encases a silky molten coconut core, delivering a beautifully layered Cantonese dessert that is indulgent yet never heavy.

Among the three new flavors, Mini Red Bean Paste with Mandarin Peel Mooncake embodies authentic traditional charm. Made with 10‑Year Aged Xinhui Mandarin peel and premium Tianjin red beans, slow-cooked into a smooth, velvety paste. The subtle bitter-sweet citrus aroma perfectly cuts through the paste’s mellow sweetness. Encased in a traditional syrup crust, rested overnight and baked to golden perfection. A refined Mid‑Autumn indulgence with heritage and harmony in every bite.

Mini Lava Custard Mooncakes return by popular demand. This crowd favorite blends premium New Zealand butter, French cream, and Japanese flour blended with rich salted egg yolks, then infused with creamy custard and coconut milk for a silky lava center. A gentle cut lets the luscious molten heart cascade slowly, blending savory salted egg yolk aroma with buttery creaminess for a satisfying, perfectly balanced flavor.

Timeless Classics: Handcrafted Mastery Preserving Heritage Truths

Though newmooncakeflavors captivate for a moment, the classics glow with lasting brilliance. For generations of Hong Kong families, Lotus Seed Paste Mooncakes with Double Yolks and Mixed Nuts Mooncakes with Chinese Ham have been more than festive delicacies, they are cherished memories anchored to the Mid-Autumn dining table. Yung Kee’s Lotus Seed Paste Mooncakes with Double Yolks celebrate tradition and craftsmanship. Made with premium Xiang lotus seeds-praised as “China’s finest”-slow‑cooked for over three hours with pure cane sugar, creating a smooth, velvety filling that never turns grainy. This classic relies entirely on precise heat control and technique of master chefs. Hand‑rolled pastry and salted egg yolks complete this timeless creation, bringing comforting richness. Harmonious layers of lotus fragrance, gentle sweetness and savoury yolk notes form an enduring classic.

Behind the seemingly simple Mixed Nuts Mooncakes with Chinese Ham lies a recipe that tests craftsmanship most rigorously. Five selected nuts – walnuts, olive kernels, melon seeds, sesame, and almonds – are blended with Jinhua ham. Master chefs rely on decades of experience to achieve the exact mixing pressure and ingredient proportions, ensuring the filling remains delightfully textured rather than dense. Every bite delivers a crisp nuttiness followed by the savory richness of cured ham, creating a deeply harmonious and unforgettable finish.

Four Themed Gift Box Combinations to Meet Diverse Gifting Needs

This year’s mooncake gift boxes retain the elegant packaging design embodying exquisite Eastern aesthetics, with brand-new assortments tailored to cater to diverse customer preferences:

• ⁠⁠”EMBRACE” Mooncake Set: One Lotus Seed Paste Mooncake with Double Yolks and one Mixed Nuts Mooncake with Chinese Ham – conveying festive reunion blessings through timeless classic tastes.
• ⁠”APPRECIATE” Mooncake Set: One Lotus Seed Paste Mooncake with Double Yolks and four Mini Moon Quartet – offering a multi-layered journey of distinct Mid-Autumn flavors.
• ⁠”CHASE” Mooncake Set: One Mixed Nuts Mooncake with Chinese Ham and four Mini Moon Quartet – where nutty, savory richness complement delicate sweetness, bringing a thoughtful gourmet touch to the festive season.
• “ENRICH” Mooncake Set: Eight Mini Moon Quartet – gathering a delightful array of mini mooncakes in one box to savor a rich spectrum of unique flavors.

Festive Greetings to Accompany Your Journey

Following the launch of the sales counter at West Kowloon High-Speed Railway Station last year, Yung Kee is making a return to the Hong Kong Duty Free shop (within the restricted area) at West Kowloon High-Speed Railway Station this year. Whether as thoughtful gifts for loved ones or prestigious corporate presents, a box of mooncakes allows authentic Cantonese flavors from Hong Kong to travel alongside you.

Starting from today, Yung Kee offers exclusive limited-time rewards for sharing festive joy:

* Special Offers are valid at Yung Kee Restaurant and Yung’s Bistro outlets only. Offers are subject to terms and conditions.

# For promotions at our online store and the Hong Kong Duty Free at High-Speed Rail Station, please check the online store for details or inquire with in-store staff.

Sales Locations：

Yung Kee Restaurant

• 32-40 Wellington Street, Central, Hong Kong
• Tel: (852) 2522 1624

Yung’s Bistro

• Taikoo Place: Shop 1-2, G/F, Dorset House, 979 King’s Road, Quarry Bay

Tel: (852) 2523 3123

• K11 MUSEA: Unit 704, 7/F, K11 MUSEA, Tsim Sha Tsui

Tel: (852) 2321 3800

Hong Kong Duty Free
West Kowloon Station (Cross Boundary Restricted Area), 3 Austin Road West, Tsim Sha Tsui, Kowloon

Online Store: https://yungkee.buys.hk/html/eshop-checkout-zh.html

Redemption Details：
Yung Kee Restaurant Redemption Period: September 1 – September 22, 2026
Yung’s Bistro (K11 MUSEA and Taikoo Place) Redemption Period: September 1 – September 20, 2026

Enquiry & Ordering:
General Enquiries: 5599 2800
Corporate Orders: 5599 3123

For high-resolution images, please visit:
https://drive.google.com/drive/folders/1wL88R5pndVXL2aKO2793-DHDaETvcZR9

Hashtag: #鏞記 #YungKee #鏞鏞藝嚐館 #Yung’sBistro #中秋節 #月餅

The issuer is solely responsible for the content of this announcement.

Yung Kee Restaurant

Located in the heart of Hong Kong, Yung Kee Restaurant is a culinary institution steeped in history and local culture. Growing alongside Hong Kong for over eight decades, the restaurant has attracted countless tourists and local gastronomes with its signature charcoal-roasted specialties and authentic Cantonese cuisine at various price points. The four-story dining space offers unique experiences, while preserving local culture through its distinctive architecture and carefully curated historical artifacts, creating a Living Museum where guests can immerse themselves in art and culture.

Yung’s Bistro

Yung’s Bistro is the first contemporary brand under the renowned Yung Kee Restaurant, launched at K11 MUSEA in 2019. Guided by the philosophy “Taste of Art, Made with Heart,” the brand builds on classic Cantonese flavors and Hong Kong’s food culture while giving them a more contemporary edge.

• Chubb Care Critical Illness Series offers comprehensive protection for healthy individuals, cancer survivors and individualswith cardiovascular disease or diabetes histories, helping address a significant coverage gap in Hong Kong.
• Market-firstflexible payout options and unified cross-border premiums offer advanced financial support and post-recovery care.

HONG KONG SAR – Media OutReach Newswire – 13 August 2026 – Chubb Life Hong Kong today announced the launch of the “Chubb Care Critical Illness Series”, a flagship suite of health solutions featuring market-first flexible payout options and unified cross-border premiums, designed to give customers greater flexibility and financial control at every stage of their health journey. The series aims to address a significant coverage gap in Hong Kong by offering comprehensive protection for customers across a range of health backgrounds,including those with a history of critical illness.

With private healthcare costs in Hong Kong ranked the second highest in the world¹, continuous critical illness protection against recurring or subsequent major illnesses remains increasingly crucial. At the same time, individuals with a history of critical illness often face application rejections, policy exclusions or higher premiums. Chubb Care Critical Illness Series addresses these varied health profiles through four distinct options:

• Chubb Every Care Critical Illness Insurance Plan (“Chubb Every Care”): Designed for healthy individuals, with coverage for 146 illnesses and up to 800% protection².
• Chubb Cancer / Cardio / Diabetes Care Critical Illness Insurance Plan (“Chubb Cancer/ Cardio/ Diabetes Care”): Designed for cancer survivors, individuals with cardiovascular disease and those with well-controlled diabetes respectively with a simplified underwriting approach, offering up to 300% protection³ for up to 128 illnesses⁴.

The series is designed for customers with different health needs and encompasses groundbreaking first-in-market⁵ features including:

• Flexible payout options: Offers a standby cash option for an additional 100% of the sum assured, or an ongoing protection option for continuing coverage up to 5 additional claims under Chubb Every Care.
• Reimbursement for out-of-pocket items⁶: Covers eligible self-financed drugs and/or privately purchased medical items⁷ for cancer, heart attack⁷, and stroke⁷.
• Post-recovery & advanced care⁶: Delivers extra 20% of the Sum Assured for appearance restoration and side-effects resulting from cancer and its treatments, plus an additional 20% of the Sum Assured if a condition progresses to advanced stage cancer, severe heart attack⁷ or severe stroke⁷.

To support customers residing in both Mainland China and Hong Kong, the series also features unified premiums for Hong Kong and Chinese Mainland customers and recognizes health reports from designated mainland hospitals. Other key benefits include a simplified underwriting process, an exceptional leverage ratio and one-stop dedicated medical case management team led by a family doctor⁸.

Alex Wong, Chief Customer Proposition Officer of Chubb Life Hong Kong, said: “Many individuals who have recovered from a critical illness may find themselves without insurance protection after their first diagnosis, leaving them financially exposed if the illness returns. With the launch of Chubb Care Critical Illness Series, we are helping to address this uncertainty by giving customers greater choice and practical support at every stage of their health journey, so they and their families can navigate the future with confidence. Chubb Life Hong Kong is committed to delivering forward-looking health solutions that respond directly to our customers’ evolving needs.”

For more information about Chubb Care Critical Illness Series, please refer to: https://www.chubb.com/hk-en/personal/chubb-every-care-critical-illness-insurance-plan-series.html.

This article is intended for general reference only and should not be regarded as professional advice, recommendation and does not form part of the policy. This article should be read along with other materials which cover more product information. Such materials include, but not limited to, product brochures setting out key product risks, policy provisions that contain the detailed terms and conditions, benefit illustrations (if any), policy documents and other relevant promotional or marketing materials, which are all available upon request. You might also consider seeking independent professional advice if needed. This article is intended to be displayed in Hong Kong only and does not construe as an offer to sell or solicitation to buy or provision of any insurance products outside Hong Kong. The above plan is a standalone policy and may be purchased independently without bundling with other insurance products.

Appendix

About Chubb Care Critical Illness Series

• Product Nature: Critical illness protection insurance series (with savings element)
• Target Segments:
• Chubb Every Care Critical Illness Insurance Plan (“Chubb Every Care”): Healthy individuals
• Chubb Cancer / Cardio / Diabetes Care Critical Illness Insurance Plan (“Chubb Cancer/ Cardio/ Diabetes Care”): Customers with medical histories (i.e. cancer, cardiovascular disease and diabetes histories)
• Four plan options under the series:

Chubb Every Care Critical Illness Insurance Plan

Chubb Cancer/Cardio/Diabetes Care Critical Illness Insurance Plan

Notes:

1. Assume that payout for Minor Illness Benefit has reached 90% of the Sum Assured; Protection Revival Benefit and Extra Coverage Benefit have been paid with the Major Illness Benefit; Ongoing Protection Option was selected for the payment of Major Illness Benefit; Multiple Protection Major Illness Benefit has been paid five times; and the Out-of-Pocket Items Benefit, Appearance Care Benefit, and Embrace Life Benefit have all been paid out at respective maximum benefit payable.
2. It is based on a comparison with other participating critical illness protection plans offered by Composite and Long-Term Businesses as identified in the Register of Authorized Insurers by Insurance Authority as of 22 May 2026.
3. Assume that payout for Minor Illness Benefit has reached 90% of the Sum Assured; Protection Revival Benefit has been paid with the Major Illness Benefit; Multiple Protection Major Illness Benefit has been paid; and the Out-of-Pocket Items Benefit, Appearance Care Benefit, and Embrace Life Benefit have all been paid out at respective maximum benefit payable.
4. Chubb Cardio Care Critical Illness Insurance Plan provides coverage for 43 Minor Illnesses and Major Illnesses, while Chubb Cancer / Diabetes Care Critical Illness Insurance Plan provides coverage for 128 Minor Illnesses and Major Illnesses.
5. Subject to the provisions of Coverage Unlock Privilege.
6. For Chubb Cancer Care Critical Illness Insurance Plan, this is subject to Cancer Lien. Please refer to the product brochure of respective insurance plan for details.
7. Subject to the terms and conditions. It is not applicable to Chubb Cardio Care Critical Illness Insurance Plan. Please refer to the product brochure of respective insurance plan for details.
8. For the avoidance of doubt, Coverage Unlock Privilege and any unlocked benefits are subject to the terms and conditions of the Policy, including provisions relating to lapse and reinstatement.

Hashtag: #ChubbLife

The issuer is solely responsible for the content of this announcement.

About Chubb

Chubb is a world leader in insurance. With operations in 54 countries and territories, Chubb provides commercial and personal property and casualty insurance, personal accident and supplemental health insurance, reinsurance and life insurance to a diverse group of clients. The company is defined by its extensive product and service offerings, broad distribution capabilities, exceptional financial strength and local operations globally. Parent company Chubb Limited is listed on the New York Stock Exchange (NYSE: CB) and is a component of the S&P 500 index. Chubb employs approximately 45,000 people worldwide. Additional information can be found at: www.chubb.com.